Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful diligently but unsuccessfully to create an one-time therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be used is actually an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination treatment in the curing of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of the last few shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What In order to Do When It’s Too Good To Be True?”, set out the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such a highly marketing picture in the Uptick Newswire employment interview which I came away with an inadequate viewpoint of the business.

Irony of irony, my poor impression of the business enterprise has grown steadily, although the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this technology as well as linked intellectual property from Progenics to CytoDyn, and approximately 25 million mg of majority drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 zillion) along with the very first new drug program approval ($five million), and also royalty payments of 5 percent of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous therapies and numerous indications, it’s this individual treatments as well as a “broad pipeline of indications” since it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially beneficial therapy of dozens of indications.

The opening banner of its on its site (below) shows an energetic business with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple publications in addition to multiple presentations.

Might all this be smoke cigarettes and mirrors? That’s a question I have been asking myself from the very beginning of my interest in this particular company. Judging by the multiples of a huge number of diverse commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this particular question.

CytoDyn is a classic battleground, or perhaps some might say cult stock. Its adherents are fiercely shielding of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *